Article

Vasculitides of the gastrointestinal tract

Department of Pathology, Toronto General Hospital/University Health Network, Toronto, ON, Canada.
Seminars in Diagnostic Pathology (Impact Factor: 1.8). 05/2009; 26(2):77-88. DOI: 10.1053/j.semdp.2009.06.001
Source: PubMed

ABSTRACT Systemic vasculitis is often not considered as a possible diagnosis by clinicians because of its low prevalence compared with other more common diseases. Vasculitis can affect any end organ, and it is therefore often missed early on in disease progression. Gastrointestinal (GI) manifestations of vasculitis are considered rare and the presentation is often nonspecific. However, if there is significant involvement of the major vessels of the gastrointestinal system, life-threatening sequelae, including perforation and bowel ischemia, may occur. This makes early and immediate management crucial to improve long-term morbidity and mortality. Diagnosis of various GI vasculitides often relies on correlation of clinical manifestations with pathology and additional investigations. This paper reviews the various vasculitides that affect the GI tract, including systemic lupus erythematosus, mixed connective tissue disease, Henoch Schönlein purpura, polyarteritis nodosa, Churg-Strauss syndrome, Wegener's granulomatosis, microscopic polyangiitis, enterocolic lymphocytic phlebitis, and Behcet's disease. Segmental arterial mediolysis, mistakenly believed to be a vasculitis, is also discussed.

0 Followers
 · 
94 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Les vascularites systémiques peuvent être primitives, classées selon le calibre des vaisseaux atteints, ou secondaires, conséquence d’une infection, d’une prise médicamenteuse, d’un cancer ou d’une autre maladie systémique comme la polyarthrite rhumatoïde. Des manifestations digestives peuvent survenir, à des fréquences variables, au cours de ces vascularites et révèlent la maladie chez environ 15 % des patients. Les douleurs abdominales, les nausées, les vomissements ou les diarrhées sont fréquents, mais peu spécifiques. Une inflammation, un infiltrat purpurique et/ou nécrotique et des ulcérations (parfois d’allure granulomateuse) des muqueuses sont possibles. Les atteintes ischémiques, les infarctus et les perforations intestinales, surtout de l’intestin grêle, sont plus graves, de même que les atteintes pancréatiques et les hémorragies digestives (notamment par rupture de microanévrismes). La prise en charge combinée médicale, et chirurgicale si nécessaire, doit être précoce. La survie à dix ans des patients atteints de vascularite systémique nécrosante primitive est, aujourd’hui, de l’ordre de 80 %, en l’absence d’atteinte digestive ou si les manifestations digestives sont mineures. Le taux de survie à cinq ans n’est, par contre, que de 56 % en cas de manifestation digestive grave, chirurgicale. Primary systemic vasculitides are rare and primarily classified according to the size of the vessels predominantly affected. Secondary vasculitides can be caused by infection or drug or develop as a complication of cancer or other systemic disease like rheumatoid arthritis. Gastrointestinal manifestations occur at variable frequencies in vasculitis patients and may reveal the disease (15% of the patients). Abdominal pain, nausea, vomiting, and diarrheas are common, but non specific, manifestations. Mucosal inflammation, purpuric infiltrate or necrosis and ulceration (possibly with a granulomatous appearance) can also be observed. Gastrointestinal ischemia, bowel infarction, intestinal perforation, especially of the small bowel, pancreatitis, and gastrointestinal bleeding are more severe manifestations. Prompt and combined medical and, when necessary, surgical management is mandatory. Ten-year survival rate of patients with primary systemic necrotizing vasculitides is now about 80% in the absence of severe visceral involvement or in case of only minor gastrointestinal manifestations. Conversely, at 5 years, survival rate is only 56% for patients with severe and surgical gastrointestinal manifestations. Mots clésVascularite-Perforation-Ischémie mésentérique-Vaisseau KeywordsVasculitis-Perforation-Mesenteric ischemia-Vessel
    Côlon & Rectum 02/2010; 4(1):34-41. DOI:10.1007/s11725-010-0201-5
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Polyarteritis nodosa is a form of vasculitis that affects several organs. Gastrointestinal involvement is frequent, but cases in which the gastrointestinal tract is the only site of disease are rare. In this paper, we report a case of a 40 -year- old patient with polyarteritis nodosa restricted to small part of the small intestine, which underwent resection and anastomosis. Laparotomy was performed despite normal radiological findings. He underwent resection of the infracted segment. Histopathological examination confirmed the diagnosis. Thus, a pathological diagnosis of ischaemic infarction due to polyarteritis Nodosa (PAN) was made. The patient had no other signs of chronic vasculitis and for this reason surgical treatment resolved the clinical symptoms.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To evaluate the clinical characteristics of lupus mesenteric vasculitis (LMV) and identify the potential factors and appropriate treatments that are associated with disease relapse and prognosis inLMV. Methods A retrospective cohort study was performed among patients admitted to the 1st Affiliated Hospital of Sun Yet-sen University between 2002 and 2011. Demographic information, clinical symptoms, laboratory findings, imaging characteristics like abdominal CT scan, ultrasonography, medications including corticosteroid, cyclophosphamide and other immunosuppressive agents, and outcomes were documented. The endpoints of the study were defined as occurrence of severe complications which needed surgical intervention, disease recurrence, or death. Results Ninty-seven out of 3823 systemic lupus erythematosus (SLE) patients were diagnosed as mesenteric vasculitis with the overall prevalence of 2.5%. Among these 97 LMV patients, 13 died because of serious complications (13/97, 13.4%) and 2 presented intestinal perforation during the induction therapy stage. The logistic regression multivariate analysis indicated that leucopenia [peripheral WBC,odds ratio (OR) = 0.640,95% confidence interval (CI ) 0.456~0.896,P =0.009], hypoalbuminemia (serum albumin,OR= 0.891,95% CI 0.798~0.994,P =0.039) and elevated serum amylase (OR=7.719,95% CI 1.795~33.185,P =0.006) were positively associated with the occurrence of serious complications, while intravenous cyclophosphamide (CYC) therapy inhibited the occurrence of serious complications (OR= 0.220, 95%CI 0.053~0.903, P =0.036). Seventy-nine patients who achieved remission were followed-up for 2 to 96 months and 18 cases experienced disease relapse (18/79, 22.8%). The statistical analysis adjusted by Cox proportional hazards models indicated that, high dose CYC therapy (≥1.0 g/m2 per month) was a protective factor for disease relapse and led to better outcomes [hazard ratio (HR)=0.209, 95% CI 0.049~0.887, P =0.034], while the severe thickness of the bowel wall (>8 mm) was a risk factor (HR=7.308, 95%CI 1.740~ 30.696, P =0.007). LMV and lupus cystitis occurred concurrently in 22 (22.7%, 22/97) patients, and the symptoms of urinary tract resolved after treated with corticosteroid and immunosupressants. Conclusion LMV is one of the serious complications of SLE with high mortality. The current study demonstrated that leukopenia, hypoalbuminemia and elevated serum amylase were associated with severe adverse events, while CYC therapy led to better outcomes during remission-induction stage. Severe thickness of the bowel was a risk factor while high dose CYC therapy was a protective factor for disease relapse in intensification therapy stage. It’s necessary to evaluate the urinary tract involvement once LMV was diagnosed due to the frequent coexistence of these two diseases.
    Seminars in arthritis and rheumatism 01/2013; DOI:10.1016/j.semarthrit.2013.11.005 · 3.63 Impact Factor